SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Giallongo, Cesarina ^a   La Cava, Piera ^a   Tibullo, Daniele ^a   Barbagallo, Ignazio ^a   Parrinello, Nunziatina ^a   Cupri, Alessandra ^a   Stagno, Fabio ^a   Consoli, Carla ^a   Chiarenza, Annalisa ^a   Palumbo, Giuseppe A ^a   Di Raimondo, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

CML; Granulocytes; Imatinib; Monocytes; SPARC

Indexed keywords

IMATINIB; NILOTINIB; OSTEONECTIN;

ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MONOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; S PHASE CELL CYCLE CHECKPOINT;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES, MONONUCLEAR; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84873271623     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-60     Document Type: Article

References (42)

1. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300(5894):765-767. 10.1038/300765a0, 6960256.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(11):994-1004. 10.1056/NEJMoa022457, 12637609.
3. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344(14):1038-1042. 10.1056/NEJM200104053441402, 11287973.
4. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99(6):1928-1937. 10.1182/blood.V99.6.1928, 11877262.
5. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008, 27(4):691-705. 10.1007/s10555-008-9146-7, 18542844.
6. Funk SE, Sage EH. The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991, 88(7):2648-2652. 10.1073/pnas.88.7.2648, 51295, 2011576.
7. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol 2000, 19(7):569-580. 10.1016/S0945-053X(00)00105-0, 11102747.
8. Motamed K, Sage EH. SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J Cell Biochem 1998, 70(4):543-552. 10.1002/(SICI)1097-4644(19980915)70:4<543::AID-JCB10>3.0.CO;2-I, 9712151.
9. Kupprion C, Motamed K, Sage EH. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 1998, 273(45):29635-29640. 10.1074/jbc.273.45.29635, 9792673.
10. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci USA 1992, 89(4):1281-1285. 10.1073/pnas.89.4.1281, 48433, 1311092.
11. Chlenski A, Guerrero LJ, Peddinti R, Spitz JA, Leonhardt PT, Yang Q, Tian Y, Salwen HR, Cohn SL. Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Mol Cancer 2010, 9:138. 10.1186/1476-4598-9-138, 2895596, 20525313.
12. Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, Merup M, Nilsson L, Samuelsson J, Sander B, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007, 104(27):11406-11411. 10.1073/pnas.0610477104, 1892786, 17576924.
13. DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 2006, 20(3):426-432. 10.1038/sj.leu.2404102, 16424866.
14. Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K, Zhang Y, Kalakonda N, Nimer SD. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 2003, 122(5):728-744. 10.1046/j.1365-2141.2003.04481.x, 12930383.
15. Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, Ohanna M, Deckert M, Pasquet JM, Mahon FX, Cassuto JP, et al. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res 2010, 70(23):9659-9670. 10.1158/0008-5472.CAN-10-2034, 21098700.
16. Li K, Cai R, Dai BB, Zhang XQ, Wang HJ, Ge SF, Xu WR, Lu J. SATB1 regulates SPARC expression in K562 cell line through binding to a specific sequence in the third intron. Biochem Biophys Res Commun 2007, 356(1):6-12. 10.1016/j.bbrc.2007.01.201, 17343824.
17. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, Mok SC. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001, 159(2):609-622. 10.1016/S0002-9440(10)61732-4, 1850537, 11485919.
18. Mazzacurati L, Pattacini L, Brusa G, Mancini M, Benvenuti M, Barbieri E, Martinelli G, Baccarani M, Greenberger JS, Santucci MA. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. Hematol J 2004, 5(2):168-177. 10.1038/sj.thj.6200365, 15048068.
19. Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, Martinez-Climent JA, Montiel-Duarte C, Rifon J, Perez-Calvo J, Arbona C, et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 2005, 65(8):3264-3272.
20. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 1981, 26(1 Pt 1):99-105.
21. Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A, Conticello C, Palumbo GA, Di Raimondo F. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009, 37(4):461-468. 10.1016/j.exphem.2008.12.008, 19302920.
22. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006, 354(19):2006-2013. 10.1056/NEJMoa051140, 16687713.
23. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008, 111(5):2538-2547. 10.1182/blood-2007-07-104281, 18042796.
24. Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellstrom D, Wadenvik H. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008, 93(7):1101-1103. 10.3324/haematol.12373, 18508797.
25. Grey A, O'Sullivan S, Reid IR, Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006, 355(23):2494-2495. 10.1056/NEJMc062388, 17151376.
26. Tibullo D, Barbagallo I, Giallongo C, La Cava P, Branca A, Conticello C, Stagno F, Chiarenza A, Palumbo GA, Di Raimondo F. Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. Hematol Oncol 2012, 30(1):27-33. Epub 2011 May 5, 10.1002/hon.988, 21544849.
27. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18(2):189-218. 10.1038/sj.leu.2403241, 14737178.
28. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002, 1(5):479-492. 10.1016/S1535-6108(02)00074-0, 12124177.
29. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000, 19(21):2496-2504. 10.1038/sj.onc.1203486, 10851048.
30. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 2000, 20(4):1179-1186. 10.1128/MCB.20.4.1179-1186.2000, 85238, 10648603.
31. Sugimoto Y, Nakamura S, Okinaka K, Hirano I, Ono T, Shigeno K, Shinjo K, Ohnishi K. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells. Leuk Res 2008, 32(6):962-971. 10.1016/j.leukres.2007.11.034, 18190961.
32. Daley GQ. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors. Semin Hematol 2003, 40(2 Suppl 2):11-14.
33. Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 2005, 115(6):1492-1502. 10.1172/JCI23002, 1090471, 15902309.
34. Holtz M, Forman SJ, Bhatia R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res 2007, 67(3):1113-1120. 10.1158/0008-5472.CAN-06-2014, 17283145.
35. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil?. J Cell Biochem 2004, 92(4):679-690. 10.1002/jcb.20091, 15211566.
36. Jadersten M, Hellstrom-Lindberg E. New clues to the molecular pathogenesis of myelodysplastic syndromes. Exp Cell Res 2010, 316(8):1390-1396. 10.1016/j.yexcr.2010.02.043, 20211165.
37. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107(11):4532-4539. 10.1182/blood-2005-07-2947, 16469872.
38. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99(1):319-325. 10.1182/blood.V99.1.319, 11756187.
39. Holtz MS, Forman SJ, Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005, 19(6):1034-1041. 10.1038/sj.leu.2403724, 15815728.
40. Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, et al. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 2002, 62(24):7357-7363.
41. Palumbo GA, Romeo MA, Di Raimondo F, Giustolisi R. Interferon enhanced minimal residual disease detection in acute promyelocytic leukaemia. Br J Haematol 1997, 96(4):876-877.
42. Foresti R, Clark JE, Green CJ, Motterlini R. Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells. Involvement of superoxide and peroxynitrite anions. J Biol Chem 1997, 272(29):18411-18417. 10.1074/jbc.272.29.18411, 9218484.